Alivus Life Sciences Limited — Updates, 18-01-2025: Press Release

Glenmark Life Sciences has rebranded itself as Alivus Life Sciences, marking a significant shift following its acquisition by Nirma Limited. This change aims to enhance its global presence and reflect a renewed commitment to innovation in the active pharmaceutical ingredient (API) and contract development and manufacturing organization (CDMO) sectors. The new identity symbolizes growth and vitality. The company operates with an extensive portfolio of 161 molecules, addressing chronic therapeutic areas like cardiovascular diseases and diabetes. Alivus Life Sciences has four manufacturing facilities in India with a total installed capacity of 1,424 KL, maintaining compliance with global regulatory standards. The company's stock will trade under the symbol "ALIVUS" on the NSE, effective January 20, 2025. Alivus Life Sciences continues to focus on quality and innovation while enhancing services for its customers and stakeholders. Stakeholders should watch closely for potential growth opportunities arising from this strategic rebranding.